Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016
September 01, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments
July 14, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 ---- Growing Biomanufacturing Demand Prompts Plans for Third...
Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016
July 07, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by delivering high...
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
June 02, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued...
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
March 09, 2016 08:00 ET
|
Peregrine Pharmaceuticals Inc.
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations-- --Full Fiscal Year 2016 Revenue From Biomanufacturing...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 07, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab
February 25, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
January 20, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
December 10, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial-- --Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 07, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...